Mainolfi Nello

Chief Executive Officer, DirectorKymera Therapeutics, Inc. (KYMR) · full profile →Form 4 · filed Jul 8, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$6.0M
Net Open-Market Flow
-$6.0M
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 7, 2026Option exercise(M)50K$2.08$104K717K
Jul 7, 2026Sell(S)50K$119.00$6.0M667K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 7, 2026Option exercise(M)46K$090K
Jul 7, 2026Option exercise(M)4K$014K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-297817) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about KYMR insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001193125-26-297817"
Ask your agent
Use Arkolith to summarize insider buying and selling at Kymera Therapeutics, Inc.
over the last 90 days and cite the filings.